OCGN

Ocugen, Inc.
CAPPED RATING

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Ocugen, Inc. (OCGN) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.6 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.9
EV / EBITDA -4.4
Rev Growth YoY 11.4%
Gross Margin 0.0%
Price Return 3M -35.3%
Price Return 12M -34.3%
Catalyst Signal 0.00
Market Cap $296.4M
TTM Revenue $4.8M
Price / Sales 62.0
ROE N/A

Historical Factor Score Progression

Held C- for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.6) C+ (2.5) D (1.5) D+ (1.5) C+ (2.6) C- (2.1)
2026-11-06 C+ (2.7) C- (2.0) D- (0.8) D+ (1.7) C+ (2.7) C- (2.0)
2026-10-30 C+ (2.7) C- (1.9) D (1.4) D (1.4) C+ (2.7) C- (2.0)
2026-10-23 C+ (2.7) C- (1.9) D (1.4) D (1.4) C+ (2.6) C- (2.0)
2026-10-16 C+ (2.7) C- (1.9) D (1.4) D (1.2) C+ (2.6) C- (2.0)
Page 1 of 4